uniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE InvestmentsNewsfile Corp • 10/13/26
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share DropBusiness Wire • 10/06/26
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their RightsGlobeNewsWire • 09/30/26
uniQure Plunges on Additional Data From Huntington's Disease StudyZacks Investment Research • 09/30/26
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data UpdateSeeking Alpha • 09/30/26
uniQure Stock Crashed on Its Huntington's Data. Wall Street's Price Target Says the Selloff Went Too Far24/7 Wall Street • 09/30/26
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)PRNewsWire • 09/30/26
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing TranscriptSeeking Alpha • 09/29/26
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) BullishSeeking Alpha • 09/29/26
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS LawBusiness Wire • 09/29/26
Uniqure Plummets 40% On Another Shocking Twist For Its Huntington's DrugInvestors Business Daily • 09/29/26
UniQure's Huntington's therapy fails to significantly slow disease progression in trialReuters • 09/29/26
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's Disease Showing Continued Slowing of Disease ProgressionGlobeNewsWire • 09/29/26
QURE Submits Application for Gene Therapy for Huntington's DiseaseZacks Investment Research • 09/03/26